Clinical efficacy and biomarkers of neoadjuvant chemoimmunotherapy in locally advanced esophageal squamous cell carcinoma

Related articles

1. Effective surgical conversion after neoadjuvant immunochemotherapy improves clinical outcomes in borderline resectable esophageal cancer

   This article has 8 authors:

   1. Binwen Xu
   2. Chengcheng Zhang
   3. Tao Luo
   4. Yue Zhang
   5. Liwen Zhang
   6. Junhong Liu
   7. Guidong Shi
   8. Maoyong Fu

2. Multimodality Approach for Locally Advanced Lung Cancer: When Is Surgery Most Beneficial?

   This article has 11 authors:

   1. Riad Amin Abdeljalil
   2. Ahed Al-odwan
   3. Sakhr Alshwayyat
   4. Leen Osama Nemrawi
   5. Taher Abu Hejleh
   6. Kamal Alrabi
   7. Sameer Yaser
   8. Husam Abu Jazar
   9. Jamal Khader
   10. Anoud Al-Nsour
   11. Husam Al-Haddad

3. Adebrelimab plus chemotherapy as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma (ESCC): a single-center, phase II, single-arm, open-label clinical trial (ADENEO) protocol

   This article has 12 authors:

   1. Peng Tang
   2. Linrui Gao
   3. Siyu Zuo
   4. Ke Zhang
   5. Tierun Wang
   6. Jian Zheng
   7. Xi Chen
   8. Jie Dong
   9. Qingsong Pang
   10. Ping Wang
   11. Wencheng Zhang
   12. Tian Zhang